NRX Pharmaceuticals, Inc. Repayments of Convertible Debt
NRX Pharmaceuticals, Inc. (NRXP) reported Repayments of Convertible Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2026-03-23
- NRX Pharmaceuticals, Inc. repayments of convertible debt for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- NRX Pharmaceuticals, Inc. repayments of convertible debt for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- NRX Pharmaceuticals, Inc. repayments of convertible debt for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- NRX Pharmaceuticals, Inc. repayments of convertible debt for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- NRX Pharmaceuticals, Inc. repayments of convertible debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- NRX Pharmaceuticals, Inc. repayments of convertible debt for fiscal 2024 was $7.85M, a 153.88% increase from fiscal 2023.
- NRX Pharmaceuticals, Inc. repayments of convertible debt for fiscal 2023 was $3.09M.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 derived: sum of 3 quarters · filed 2026-03-23 | $0.00 10-K · filed 2026-03-23 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | $3.05M derived: sum of 4 quarters · filed 2026-03-23 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $0.00 10-Q · filed 2025-08-18 | $3.05M derived: sum of 3 quarters · filed 2026-03-23 | $5.69M derived: sum of 4 quarters · filed 2026-03-23 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $3.05M derived: sum of 2 quarters · filed 2026-03-23 | $5.69M derived: sum of 3 quarters · filed 2026-03-23 | $5.70M derived: sum of 4 quarters · filed 2026-03-23 |
| 2024-12-31 | $3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $5.69M derived: sum of 2 quarters · filed 2026-03-23 | $5.70M derived: sum of 3 quarters · filed 2026-03-23 | $7.85M 10-K · filed 2026-03-23 |
| 2024-09-30 | $2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $2.65M derived: sum of 2 quarters · filed 2025-11-14 | $4.80M 10-Q · filed 2025-11-14 | $5.60M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $2.16M 10-Q · filed 2025-08-18 | $2.96M derived: sum of 3 quarters · filed 2025-08-18 | $5.16M derived: sum of 4 quarters · filed 2025-08-18 |
| 2024-03-31 | $2.15M 10-Q · filed 2025-05-15 | $2.96M derived: sum of 2 quarters · filed 2025-05-15 | $5.16M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $804.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $3.00M derived: sum of 2 quarters · filed 2025-03-14 | $3.09M 10-K · filed 2025-03-14 | |
| 2023-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $2.29M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $90.00K 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |